CYP4F2-Catalyzed Metabolism of Arachidonic Acid Promotes Stromal Cell-Mediated Immunosuppression in Non-Small Cell Lung Cancer

Cancer Res. 2022 Nov 2;82(21):4016-4030. doi: 10.1158/0008-5472.CAN-21-4029.

Abstract

The identification of a role for CYP4F2-dependent metabolism in driving immune evasion in non-small cell lung cancer reveals a strategy to improve the efficacy of immunotherapy by inhibiting CYP4F2. See related article by Van Ginderachter, p. 3882.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arachidonic Acid / metabolism
  • Carcinoma, Non-Small-Cell Lung*
  • Catalysis
  • Cytochrome P450 Family 4* / metabolism
  • Humans
  • Hydroxyeicosatetraenoic Acids / metabolism
  • Immunosuppression Therapy
  • Lung Neoplasms*
  • Stromal Cells / metabolism

Substances

  • Arachidonic Acid
  • CYP4F2 protein, human
  • Cytochrome P450 Family 4
  • Hydroxyeicosatetraenoic Acids